2021
DOI: 10.1177/10600280211026338
|View full text |Cite
|
Sign up to set email alerts
|

Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma

Abstract: Objective: To identify and assess the current literature surrounding the safety, efficacy, and practical considerations of brexucabtagene autoleucel (brexu-cel) for the treatment of relapsed or refractory (r/r) mantle cell lymphoma (MCL). Data Sources: An English-based literature search was conducted using the terms “ brexucabtagene autoleucel” AND “ mantle cell lymphoma” OR “ KTE-X19”in PubMed (inception through May 1, 2021), EMBASE (inception through May 1, 2021), and ClinicalTrials.gov. Study Selection and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 14 publications
(7 citation statements)
references
References 33 publications
0
7
0
Order By: Relevance
“…KYMRIAH ™ (Tisagenlecleucel) is the first approved CAR-T cell therapy for adult patients with certain types of B-cell lymphoma (50). Three approved CAR-T cell products, YESCARTA ™ (Axicabtagene ciloleucel), TECARTUS ™ (brexucabtagene autoleucel), and BREYANZI ® (lisocabtagene maraleucel), are also approved for the treatment of B cell lymphoma (51)(52)(53). The fifth CAR-T cell product, ABECMA ® (idecabtagene vicleucel), is used for multiple myeloma therapy (54).…”
Section: Barriers To Current Car-t Cell Therapymentioning
confidence: 99%
“…KYMRIAH ™ (Tisagenlecleucel) is the first approved CAR-T cell therapy for adult patients with certain types of B-cell lymphoma (50). Three approved CAR-T cell products, YESCARTA ™ (Axicabtagene ciloleucel), TECARTUS ™ (brexucabtagene autoleucel), and BREYANZI ® (lisocabtagene maraleucel), are also approved for the treatment of B cell lymphoma (51)(52)(53). The fifth CAR-T cell product, ABECMA ® (idecabtagene vicleucel), is used for multiple myeloma therapy (54).…”
Section: Barriers To Current Car-t Cell Therapymentioning
confidence: 99%
“…Moreover, grade 3 or higher neurological toxicities were reported in 31% and 25% of patients with MCL and ALL, respectively. [38][39][40] Risk factors that contribute to neurotoxicity and CRS include a high dose of infused CAR-T cells, high tumor burden, intensive lymphodepletion therapy, and other factors that increase CAR-T cell numbers in vivo. [41][42][43][44] Some patient-related factors, such as pre-existing thrombocytopenia or endothelial activation, may further increase the risk of toxicities.…”
Section: Safety Concerns For Car-t Cell Therapiesmentioning
confidence: 99%
“…Similarly, neurological events occurred in 63% of patients with MCL and 60% of patients with ALL. Moreover, grade 3 or higher neurological toxicities were reported in 31% and 25% of patients with MCL and ALL, respectively 38–40 …”
Section: Safety Concerns For Car‐t Cell Therapiesmentioning
confidence: 99%
See 1 more Smart Citation
“…Brexucabtagene autoleucel (Tecartus) also targets CD19 with a similar scFv, but instead of 4‐1BB and CD8, it contains a CD28‐derived transmembrane and signaling domain in conjunction with CD3z (Figure 2). 23 It was first approved for r/r mantle cell lymphoma in 2020 on the basis of the findings of the ZUMA‐2 trial 24 . Subsequently, the safety and efficacy of Tecartus in patients with ALL were reported in the single‐arm, phase 2 ZUMA‐3 trial, with 56% of heavily pretreated patients achieving complete remission and a median overall survival (OS) of 18.2 months 25 .…”
Section: Brexucabtagene Autoleucelmentioning
confidence: 99%